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Abstract 20 
With the increasing emergence of antibiotic resistances old antibiotics became a valuable 21 
source to find agents suitable to address this problem. More than 20 years after the last report, 22 
our purpose was to re-evaluate the in vitro antibacterial activity of the topical agent primycin 23 
against current important bacterial pathogens. Minimal inhibitory concentrations (MIC) and 24 
minimal bactericidal concentrations (MBC) of primycin were tested in comparison with 25 
agents widely applied topically, and with those of mupirocin and vancomycin, the topical and 26 
the non-topical gold-standard anti-MRSA agents. Primycin was ineffective (MIC>64 μg/ml) 27 
against all the Gram-negative isolates tested. On the other hand, all the tested Gram-positive 28 
isolates were susceptible with MIC90 values of 0.06 μg/ml for staphylococci and 0.5-1 μg/ml 29 
for enterococci, streptococci, and P. acnes isolates, including all the multiresistant strains. 30 
Against MRSA isolates primycin showed slightly higher activity than mupirocin, and 31 
inhibited the mupirocin-resistant strains also. MBC90 values ranged from 0.25 to 2 μg/ml for 32 
the investigated Gram-positive species. The bactericidal effect proved to be concentration-33 
dependent in time-kill experiments. Spontaneous resistant mutants did not emerge in single-34 
step mutation experiments and the resistance development was very slow by serial passaging. 35 
Passaged S. aureus strains showing increased primycin MIC values exhibited elevated 36 
vancomycin and daptomycin MIC values also. Though elucidation of the mechanisms behind 37 
warrants further investigations, these correlations can be related to development of 38 
vancomycin-intermediate phenotype. From the point of view of medical practice it is 39 
noteworthy that the increased primycin MIC values remained far below the concentration 40 
accessible by local application of the agent. These data make primycin a remarkable object of 41 
further investigations as well as a promising candidate for topical application against 42 
multiresistant Gram-positive pathogens. 43 
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Introduction 46 
 47 
Primycin is a natural antibiotic complex marketed solely in Hungary under the brand name 48 
Ebrimycin
®
 gel. The agent which was described for the first time in the Nature in 1954 49 
(Vályi-Nagy et al.), possesses antibacterial and moderate antifungal activity. For toxicity 50 
reasons, only topical application is warranted, in which way it causes no adverse effect due to 51 
negligibly poor absorption (Vályi-Nagy and Kelentey, 1960). The topical alcoholous gel 52 
formulation of primycin, Ebrimycin
®
 gel is highly effective in the treatment of skin infections 53 
like acne, impetigo, and pyodermas proved by clinical studies (Bíró and Várkonyi, 1987; 54 
Mészáros and Vezekényi, 1987). Primycin is a mixture of homologous components belonging 55 
to non-polyene polyketide molecules with a 36-membered lactone ring and a terminal 56 
guanidine moiety on a side chain (Frank et al., 1987) (Fig. 1). It is thought to act on bacteria 57 
by disorganizing the cell membrane, resulting in a dose dependent increase of ion 58 
permeability and conductivity (Horváth et al., 1979). An enhanced leakage of nucleotides was 59 
also shown in P
32 
labeled cultures of Bacillus subtilis (Horváth et al., 1979). The effect of 60 
primycin was recently studied on yeasts confirming the action also on the cell membrane 61 
(Virág et al., 2010; 2012 a; 2012b; 2012c). Primycin can not be classified into any of the 62 
known major groups of antimicrobial agents, also in Bryskier's encyclopedia it is treated as a 63 
separate entity (Bryskier, 2005). 64 
Though primycin (Ebrimycin
®
 gel) has been successfully used for decades in dermatologic 65 
indications, nowadays it has a share of only ~5% in the even small Hungarian market of 66 
topical antimicrobial medicinal products. Partly, this may be due to the very limited, outdated, 67 
and in some aspects even contradictory literature available on the substance. This applies also 68 
to its antibacterial activity. The original research papers addressing the issue reported minimal 69 
inhibitory concentration (MIC) values in a range of 0.02 – 0.5 μg/ml for staphylococci and 70 
enterococci including isolates resistant to other antibiotics, however, without denominating 71 
those agents (Vályi-Nagy et al., 1954; Úri and Actor 1979; Úri, 1986). Out of these papers, 72 
only one (Úri and Actor 1979) communicated direct information on the effect of primycin 73 
against Gram-negatives claiming that it presented with no activity. Another publication 74 
concerning the pharmacodynamics of primycin only referred to the Nature paper when 75 
describing its activity against Gram-negative bacteria in a concentration hundred times higher 76 
than for Gram-positives (Horváth et al., 1979). The referred paper (Vályi-Nagy et al., 1954), 77 
however, does not contain such information at all. Effect against Gram-negatives in higher 78 
concentrations was also mentioned in a review publication referring mostly to non accessible 79 
industrial records (Nógrádi, 1988). Regarding Gram-positives, this publication assigns MIC 80 
ranges of primycin as 0.02-0.1 μg/ml for Staphylococcus spp. and Streptococcus spp., 1-10 81 
μg/ml for Enterococcus spp., and <0.1 μg/ml for Propionibacterium acnes. While primycin 82 
was often claimed to be effective on bacteria resistant to other antibiotics, only a single Gram-83 
positive strain, namely S. aureus ATCC 25923, was reported to be resistant to primycin. In 84 
the studies of Úri and Actor (1979) it was not inhibited even by 2 μg/ml primycin, the highest 85 
concentration tested, and Nógrádi (1988) reported a MIC value of 25 μg/ml for it. 86 
While antifungal activity of primycin has recently been re-evaluated on yeasts (Nyilasi et al., 87 
2010; Virág et al., 2012 b) even the latest studies on its antibacterial activity were performed 88 
more than 20 years ago on strain collections not reflecting the present resistance situation. For 89 
this reason, we re-investigated the antibacterial efficacy of primycin against recent clinical 90 
isolates and international reference strains of several important bacterial pathogens. Current 91 
multiresistant strains, i.e. methicillin-resistant staphylococci and vancomycin-resistant 92 
enterococci, to which no data exists on primycin susceptibility, were also involved in the 93 
study. We compared the efficacy of primycin with that of other antibiotics widely used as 94 
topical agents in dermatology, ophthalmology, and oto-rhino-laryngology, and with that of 95 
vancomycin as a gold standard against multiresistant Gram-positive bacteria. Re-investigation 96 
and characterization of bactericidal activity and pharmacodynamics of primycin was also a 97 
purpose of the study. To help the estimation of long-term utility of the agent we also 98 
addressed the frequency of spontaneous resistance, resistance development and possible 99 
cross-resistances. 100 
 101 
Materials and Methods 102 
 103 
Clinical isolates 104 
Clinical isolates of methicillin-susceptible S. aureus (MSSA) (n=10), methicillin-resistant S. 105 
aureus (MRSA) (n=20), methicillin-susceptible coagulase-negative Staphylococcus spp. (MS-106 
CNS) (n=10), methicillin-resistant coagulase-negative Staphylococcus spp. (MR-CNS) 107 
(n=10), vancomycin-sensitive Enterococcus spp. (VSE) (n=20), viridans group streptococci 108 
(n=20), ESBL-producing Klebsiella spp. (n=10), non-ESBL-producing Klebsiella spp. 109 
(n=10), Pseudomonas aeruginosa (n=10), Escherichia coli (n=10), and Proteus spp. (n=10) 110 
were collected and identified by conventional routine methods at the Department of Medical 111 
Microbiology and Immunology, Medical School, University of Pécs. 112 
Twenty isolates of P. acnes were collected and identified at the Institute of Clinical 113 
Microbiology, Faculty of Medicine, University of Szeged. 114 
Penicillin-susceptible (n=10) and penicillin-resistant (n=10) Streptococcus pneumoniae 115 
strains were collected at the Institute of Medical Microbiology, Faculty of Medicine, 116 
Semmelweis University, Budapest. The serotypes and penicillin susceptibility status of these 117 
strains were previously published (Dobay et al., 2003). 118 
Ten isolates of Enterococcus spp. with decreased vancomycin susceptibility including two 119 
resistant (VRE) strains were collected by the Department of Medical Microbiology, Faculty 120 
of Medicine, University of Debrecen. These isolates were characterized for the genetic 121 
background of vancomycin resistance by standard genetic methods previously described 122 
(Dombrádi et al., 2009; 2012).  123 
 124 
International reference strains 125 
In the susceptibility tests, the following internal quality control strains were used: S. aureus 126 
ATCC 29213, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, E. coli ATCC 25922. 127 
Furthermore, for primycin Enterococcus hirae ATCC 8043 was also taken for quality control, 128 
as this strain is applied to assess the quality of the individual batches of primycin in industrial 129 
production. Beside these quality control strains primycin susceptibilities of S. aureus ATCC 130 
43300 (MRSA), heterogeneous vancomycin-intermediate S. aureus (hVISA) ATCC 700698, 131 
vancomycin-intermediate S. aureus (VISA) ATCC 700699, mupirocin-resistant S. aureus 132 
ATCC BAA-1708, E. faecalis ATCC 51299 (VRE), P. acnes ATCC 11828, and the presumed 133 
primycin-resistant S. aureus ATCC 25923 strains were also determined. 134 
 135 
Antimicrobial agents  136 
Antimicrobial agents used: primycin (PannonPharma Pharmaceutical Ltd, Hungary), 137 
ofloxacin (Zheijang Apeloa Pharmaceutical Co. Ltd, China), tobramycin (Chongquing Daxin 138 
Pharmaceutical Co. Ltd, China), oxytetracycline (LongMarch Pharmaceutical Co. Ltd, 139 
China), erythromycin (Sigma-Aldrich), neomycin (Sigma-Aldrich), gentamicin (Sigma-140 
Aldrich), mupirocin (Sigma-Aldrich), vancomycin (Sigma-Aldrich), oxacillin (Sigma-141 
Aldrich), and daptomycin (Novartis, Germany). Handling, storage and preparation of 142 
solutions were carried out according to the instructions of the manufacturers. Dimethyl-143 
sulfoxide (Biolab, Hungary) was used as a solvent for primycin. The organic solvent was 144 
present in the final medium in 1% (v/v) and did not influence the growth of any tested strain 145 
in this concentration. 146 
 147 
MIC testing 148 
The MIC of each isolate was determined by broth microdilution method according to the 149 
CLSI standards (2012 a, 2012 b). For susceptibility testing of aerobically growing bacteria, 150 
Mueller Hinton broth (Biolab, Hungary) was used. Cation-adjusted Mueller-Hinton broth 151 
(Biolab, Hungary) supplemented with 5% (v/v) lysed horse blood (Liofilchem, Italy) was 152 
used for Streptococcus spp. including S. pneumoniae isolates. When testing daptomycin, Ca
2+
 153 
content of the broth was adjusted to 50 μg/ml. In case of P. acnes isolates Brucella Broth 154 
(Biolab, Hungary) supplemented with 1 μg/ml vitamin K1, 5 μg/ml hemin, and 5% (v/v) lysed 155 
horse blood was applied. Concentration ranges for the individual agents were as follows: 156 
primycin and oxacillin: 0.015-64 μg/ml; vancomycin, oxytetracycline, tobramycin, and 157 
neomycin: 0.06-32 μg/ml; gentamicin, erythromycin, ofloxacin, and daptomycin: 0.03-16 158 
μg/ml; mupirocin: 0.03-1024 μg/ml. The inocula of test strains were prepared in sterile 0.9 % 159 
w/v saline solution from overnight plate cultures, and adjusted to 0.5 McFarland unit, and. 160 
diluted into the broth medium to reach the working concentration of approximately 5 × 105 161 
colony forming units (CFU) per ml. Isolates of aerobically growing species were incubated 162 
for 20-24 hours at 37 °C in ambient air while P. acnes isolates were incubated for 48 hours at 163 
37 °C under anaerobic condition, prior to MIC reading. The MIC was defined as the lowest 164 
antibiotic concentration at which no growth was detectable with the unaided eye compared to 165 
the control wells. CLSI quality control MIC ranges were applied for ofloxacin, tobramycin, 166 
erythromycin, gentamicin, mupirocin, vancomycin, oxacillin, and daptomycin (CLSI, 2014). 167 
For neomycin we considered target MICs to be 1 and 4 μg/ml for S. aureus ATCC 29213 and 168 
E. coli ATCC 25922, respectively, reported by Bera et al. (2010). In case of oxytetracycline 169 
target MIC of 1 μg/ml for E. coli ATCC 25922 was applied according to Miller et al. (2005). 170 
At least two independent experiments were performed in duplicates for every isolate. 171 
 172 
MBC testing 173 
Minimal bactericidal concentration (MBC) testing was performed in accordance with the 174 
CLSI guideline (1999). Duplicate samples of 0.01 ml taken from wells showing no growth 175 
were subcultured on agar plates (blood agar for streptococci and anaerobic blood agar for P. 176 
acnes isolates) immediately after the MIC reading. Colonies were counted after 20-24 h 177 
incubation at 37 °C in ambient air (anaerobic incubation at 37 °C for 48 h for P. acnes 178 
isolates). The MBC was defined as the lowest concentration causing ≥3 log10 decrease of CFU 179 
count resulting in no more than five colonies on the plates. 180 
 181 
Time-kill assays 182 
Time-kill assays were also performed according to the CLSI guideline (1999). Test media and 183 
preparation of inoculum suspensions were the same as for the MIC measurements. 184 
Antimicrobial concentrations of one-, two-, four-, and eight-fold of the MICs were applied. 185 
The initial inoculum concentration was aimed to be 5 × 105 CFU/ml. Reaction tubes with 10 186 
ml final volume were incubated at 37 °C in ambient air for 24 hours. Serial tenfold dilutions 187 
of 0.1 ml samples removed at 0, 1, 2, 4, 8, 12, and 24 h were made in sterile 0.9 % w/v saline 188 
solution, and 0.01 ml aliquots of these suspensions and the undiluted sample were cultured in 189 
duplicates on agar plates similar to those used in MBC measurements. Colonies were counted 190 
after incubation similar to that of MBC plate cultures. Limit of detection was 1.7 log10 191 
CFU/ml. Effects resulting ≥3 log10 decrease in CFU counts were interpreted as bactericidal. 192 
 193 
Determination of spontaneous mutant frequencies 194 
Single-step mutation tests were conducted to determine spontaneous mutant frequencies 195 
according to Woosley et al. (2010). One ml of 4 McFarland turbid suspensions made from 196 
overnight colonies was plated on agar plates containing two- and fourfold of the MIC 197 
regarding the strains tested and incubated for 48 hours at 37 °C in ambient air. The CFU count 198 
per ml of every inoculum suspension was determined by plating serial tenfold dilutions on 199 
agar plates and counted after 24 h incubation. Ratios of the resistant mutants and the total 200 
number of bacteria plated were considered as the frequency of mutants. 201 
 202 
Passaging studies 203 
CLSI standard broth microdilution method used in susceptibility tests was utilized also in 204 
passaging studies according to Woosley et al. (2010). Contents of the last wells of 205 
microdilution panels showing growth were used to prepare inoculum suspensions for the next 206 
MIC measurements. This procedure was repeated daily for 21 days after which three passages 207 
on antibiotic free agar plates were performed prior to testing for reversion. 208 
 209 
 210 
Results 211 
 212 
Susceptibility test results 213 
In the susceptibility tests all of the examined Gram-positive clinical isolates proved to be 214 
susceptible to primycin, showing unimodal MIC distribution within genera (Table 1). In most 215 
cases the MIC90 values of primycin were lower than those of the comparative antimicrobials, 216 
especially for staphylococci. No relationship could be observed between MIC values for 217 
primycin either with those of the comparator agents or with methicillin resistance of 218 
staphylococci. Efficacy of primycin was independent of serotypes or the degree of penicillin 219 
resistance in S. pneumoniae isolates (Table 2). Enterococcus isolates with decreased 220 
susceptibility to vancomycin were also susceptible to primycin with MIC values of 0.25 - 0.5 221 
μg/ml irrespectively of the species, or the type of van resistance genes (Table 3). Among the 222 
comparative agents only vancomycin was highly efficient against all the clinical isolates 223 
except the VRE ones. For all the other comparative agents prevalence of resistant isolates was 224 
reflected by high MIC50 and MIC90 values (Table 1). 225 
Primycin was ineffective against all of the tested Gram-negative bacteria. No inhibition could 226 
be detected even when a concentration of 64 μg/ml was applied. Considering these findings 227 
primycin does not seem to be a promising agent against Gram-negative pathogens, therefore 228 
we did not perform further examinations on such isolates.  229 
MBC values of primycin were also determined for the Gram-positive clinical isolates, and the 230 
agent showed bactericidal effect in all cases (Table 4). Survivors above the MIC values were 231 
found in case of most S. aureus, CNS, Enterococcus, and P. acnes isolates, but only 232 
sporadically among isolates of streptococci. These survivor bacteria showed no MIC change 233 
when re-tested. 234 
ATCC reference strains including the VRE, MRSA, hVISA, and mupirocin-resistant S. 235 
aureus showed primycin susceptibilities corresponding well to those of the clinical isolates. 236 
The only exception was the ATCC 700699 VISA strain, being the only S. aureus to reach a 237 
primycin MIC value of 0.125 μg/ml – double of all the others’ (Table 5). 238 
As the mupirocin-resistant S. aureus ATCC BAA-1708 also proved to be sensitive to 239 
primycin, we made a comparison of primycin with mupirocin on an extended collection of 240 
MRSA – the target organism of mupirocin in its primary indication of nasal decolonization 241 
(Table 6). Only one out of 20 MRSA clinical isolates showed high level mupirocin resistance, 242 
the rest of the isolates were sensitive with low MIC values. Primycin generally showed MIC 243 
and MBC values one or two dilutions lower than mupirocin, and the mupirocin-resistant 244 
MRSA clinical isolate also proved to be susceptible to primycin. 245 
 246 
Time-kill curves 247 
To assess the dynamics of the bactericidal effect of primycin, time-kill studies were 248 
performed on three reference strains, S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. 249 
pneumoniae ATCC 49619. Supporting the evaluation of the basic pharmacodynamic 250 
characteristics of primycin, parallel time-kill assays were made for comparison with 251 
vancomycin. MICs of vancomycin were 1, 4, and 0.5 μg/ml against the above mentioned 252 
strains, respectively. MBC values of vancomycin were equal to MICs in case of S. aureus 253 
ATCC 29213, S. pneumoniae ATCC 49619, but in case of E. faecalis ATCC 29212 the agent 254 
did not show bactericidal activity (MBC ≥ 32×MIC). Time-kill curves of primycin showed 255 
characteristic graphs of concentration-dependent bactericidal effect against all the three 256 
strains (Fig. 2). The agent elicited 3 log10 decrease in colony counts by 24 h in concentrations 257 
four and eight times the MIC values against S. aureus ATCC 29213. Against S. pneumoniae 258 
ATCC 49619 and E. faecalis ATCC 29212 primycin was rapidly bactericidal in 259 
concentrations four and eight times the MIC by 2 h. Time-kill curves of vancomycin showed 260 
characteristic time-dependent bactericidal effect against S. aureus ATCC 29213 and S. 261 
pneumoniae ATCC 49619, resulting in >3 log10 decrease in colony counts by 24 and 12 h, 262 
respectively. The agent showed bacteriostatic effect against E. faecalis ATCC 29212 (Fig. 2). 263 
The time-kill results harmonized well with the corresponding MIC and MBC values.  264 
 265 
Frequency of spontaneous resistance to primycin 266 
To assess frequency of spontaneous primycin-resistant mutants, eight reference strains were 267 
involved in single-step spontaneous mutation studies: S. aureus ATCC 29213, S. aureus 268 
ATCC 25923, S. aureus ATCC 43300, S. aureus ATCC 700698, S. aureus ATCC 700699, S. 269 
aureus BAA-1708, E. faecalis ATCC 29212, and E. faecalis 51299. 270 
No resistant colony was found in these experiments (mutant frequency <4.5 × 10-9 for all the 271 
strains tested). For the S. aureus ATCC 25923 strain, previously reported to be resistant to 272 
primycin (Úri and Actor, 1979), the experiment was also performed by challenging a two 273 
exponent larger population, but again, no resistant mutant emerged (mutant frequency <2.7 × 274 
10
-11
). 275 
 276 
Results of the passaging experiments 277 
While spontaneous resistant mutants did not emerge during the single-step mutation tests, we 278 
conducted a 21-day passaging study with the same strains in order to assess the selection of 279 
resistant mutants which we could also use to assess possible phenotypic cross-resistance with 280 
other antimicrobials. 281 
Only one isolate could reach fourth, and six others twice the initial MIC value, while one 282 
isolate failed to change its MIC value during the 21-day period (Table 7). This slow 283 
adaptation is in coherence with the low frequency of spontaneous mutants. Elevated MIC 284 
values of the derivative strains remained stable after three nonselective passages. 285 
 286 
Cross resistance studies 287 
Parallel MIC tests were performed with the seven strain pairs from the passaging studies to 288 
assess the phenotypic cross-resistance against vancomycin, mupirocin, gentamicin, 289 
erythromycin, ofloxacin, oxytetracycline, and oxacillin as representatives of the major 290 
antibiotic groups. Daptomycin known to act on the cell membrane was also involved in the 291 
comparison. 292 
No or only non-consequent differences could be seen between the parent and the derivative 293 
strains in susceptibilities to mupirocin, gentamicin, erythromycin, ofloxacin, oxytetracycline, 294 
and oxacillin. The absence of correlations is coherent with the uniform primycin MIC values 295 
of the clinical isolates regardless their resistance status to these agents. On the other hand, 296 
clear coincidence was found between the primycin and vancomycin MIC value changes 297 
among the passaged S. aureus strains (Table 8). While among the parent strains only the 298 
VISA ATCC 700699 showed a vancomycin MIC value of 4 μg/ml, the derivatives of the 299 
hVISA ATCC 700698 and the MRSA ATCC 43300 strains also reached this breakpoint. 300 
Further three strains changed their vancomycin MIC values from 1 to 2 μg/ml. This 301 
correlation is coherent also with the slightly higher initial primycin MIC value of the VISA 302 
ATCC 700699 strain compared to the other S. aureus strains. Six out of seven primycin-303 
passaged strains with elevated primycin MICs showed one dilution step higher daptomycin 304 
MIC values than their non-passaged counterparts. The VISA ATCC 700699 strain reached the 305 
breakpoint of daptomycin-nonsusceptibility (MIC=2 μg/ml) after passaging with primycin 306 
(Table 8). 307 
 308 
 309 
Discussion 310 
 311 
Resistance to antimicrobials is a high priority health care issue attracting worldwide attention. 312 
The emergence and spread of multiresistant bacteria stimulated numerous studies to develop 313 
more effective antibacterial agents, and also induced re-evaluation of previously known 314 
compounds not being in the focus of the present therapeutic palette. Our study effectuates the 315 
latter approach on primycin by re-investigating the efficacy of this topical agent introduced 316 
more than 50 years ago but not widely used in the present practice. 317 
Our results show that primycin possesses with high efficacy against current populations of the 318 
most frequent Gram-positive pathogens including recently emerging multiresistant strains 319 
while it is ineffective against the Gram-negative taxa tested. MIC values for Gram-positives 320 
found in our study were generally within the ranges outlined by the literature, commensurably 321 
to the lower values reported earlier (Vályi-Nagy et al., 1954; Úri, 1986; Nógrádi, 1988). The 322 
ineffectiveness of primycin against Gram-negative bacteria found in this study confirms the 323 
original data of Úri and Actor (1979). The spectrum and efficacy of primycin against Gram-324 
positive bacteria proved to be superior to that of the six comparator antibiotics widely used as 325 
topical agents and even to that of vancomycin. It turned out also to be slightly more effective 326 
in vitro than mupirocin against its primary target organism MRSA. The imminent threat of 327 
mupirocin resistance of staphylococci may also be addressed by the high primycin 328 
susceptibility of the mupirocin-resistant S. aureus strains. High efficacy of primycin against 329 
P. acnes can also be an advantage over mupirocin in dermatologic applications. 330 
The susceptibility test results of the comparative agents correspond well to the literature. For 331 
example, our data on susceptibility of MRSA isolates to ofloxacin, gentamicin, and 332 
vancomycin make almost perfect match with results of Kotlus et al. (2006). Our vancomycin 333 
MIC values were in accordance with surveillance data (Draghi et al., 2008), even concerning 334 
the slightly higher MIC values against CNS, especially MR-CNS compared to S. aureus 335 
isolates. The frequently detected resistance to the comparative agents confirms concerns about 336 
this emerging problem (Elston, 2009). Mupirocin-resistance among MRSA strains is also 337 
present, though, still not in a high rate. 338 
In our study, primycin proved to be bactericidal in concentrations equal to the MICs in case of 339 
streptococci. MBC values of enterococci and P. acnes isolates were higher than MIC values 340 
by one or two dilution steps, while in case of staphylococci this difference ranged from one to 341 
six dilution steps. These results imply the need for evaluation of the clinical relevance of the 342 
significantly lower MIC values for staphylococci. 343 
Killing dynamics of primycin can be characterized as concentration-dependent. This is 344 
coherent with an earlier study on the mechanism of action demonstrating concentration-345 
dependent effects on bacterial cell membrane permeability (Horváth et al., 1979). Time-346 
dependent killing dynamics of vancomycin against staphylococci and streptococci is a well-347 
known feature, along with the knowledge that it possesses only bacteriostatic effect on 348 
enterococci (Saribas and Bagdatli 2004). 349 
No primycin-resistant Gram-positive bacteria were found throughout the studies. Even the S. 350 
aureus ATCC 25923 strain, reported to be primycin-resistant in earlier papers (Úri and Actor, 351 
1979; Nógrádi, 1988), was consistently inhibited by primycin in our hands with a MIC value 352 
of 0.06 μg/ml. This was confirmed by several independent experiments performed on multiple 353 
specimens of the strain purchased from different culture collection sources. The reason of the 354 
resistance detected earlier was claimed to be unknown (Úri and Actor, 1979), and as this 355 
result could not be reproduced it remains without plausible explanation. We have to notice, 356 
however, that in the original research paper (Úri and Actor, 1979) no quality control was 357 
given, and the MIC values for all Staphylococcus strains were about four-eight times higher 358 
than in our study, and the other publication is a survey paper (Nógrádi, 1988) taking the data 359 
from non peer-reviewed inaccessible internal industrial reports without giving any hint to the 360 
materials and methods applied. Furthermore, this strain has never been specified and 361 
standardized for primycin susceptibility either by ATCC, by the former manufacturers of the 362 
agent or by any organizations of standardization. 363 
Based on our results, emergence of spontaneous primycin-resistant mutants is unlikely, and 364 
the resistance development is also very slow. Along with the limited use of the agent, these 365 
features may explain the absence of resistant isolates in the tested Gram-positive sample 366 
collections. 367 
The uniform primycin-susceptibility of isolates either resistant or susceptible to the 368 
comparator agents implies that the mechanisms behind the resistance to these compounds do 369 
not interfere with the effect of primycin. Consequently, no correlation was found between 370 
elevated primycin MIC values of the passaged derivatives and susceptibilities thereof to most 371 
of the other agents. This is coherent with the unique structure and action mechanism of 372 
primycin (Frank et al., 1987; Horváth et al., 1979; Bryskier, 2005). Clear coincidence with 373 
elevated primycin MIC values could be found with the vancomycin-intermediate phenotype 374 
of S. aureus. Decrease of primycin susceptibility also resulted in consequent elevation of 375 
daptomycin MIC values. These correlations suggest that mechanisms behind daptomycin-376 
nonsusceptibility by vancomycin-intermediate phenotype may also be the reasons of 377 
decreased primycin susceptibility. Thickened cell wall holding up the penetration of the large 378 
molecule (Cui et al., 2006) or alterations of the cytoplasmic membrane (Bayer et al. 2013) are 379 
possible causes of the decreased primycin susceptibility as similarly to daptomycin, primycin 380 
possesses with high molecular weight (Frank et al., 1987), and affects also the cell membrane 381 
(Horváth et al., 1979). Though the exact mechanisms behind should be confirmed by detailed 382 
studies, our results suggest that prolonged exposure to primycin in subinhibitory 383 
concentrations may lead to the development of vancomycin-intermediate phenotype and 384 
daptomycin-nonsusceptibility. On the other hand, even the passaged derivatives with their 385 
increased primycin MIC values remain definitely susceptible to the concentrations applied in 386 
the practice for topical treatment (i.e. primycin content of Ebrimycin
®
 gel is 2,000 μg/g). 387 
These facts should be taken into account when planning clinical studies and establishing 388 
dosing regimens. 389 
Taken together, we assessed the antibacterial spectrum and efficacy of primycin after more 390 
than 20 years of the last report on this subject. Consequently, this is the first study presenting 391 
data on primycin susceptibilities of currently prevalent multiresistant Gram-positive bacteria. 392 
To our knowledge, dynamics of bactericidal activity of primycin, frequency of spontaneous 393 
resistance, and resistance development have never been evaluated previously. Clear evidences 394 
were gained on the presence or absence of phenotypic cross-resistance with a number of other 395 
agents. Based on the results reported here primycin is a remarkable object for further studies 396 
with much aspects to be examined. 397 
The very extended and high efficiency of primycin against multiresistant Gram-positive 398 
bacteria can make this antibiotic particularly valuable in the clinical practice. Considering that 399 
in topical applications antibiotics can be applied in concentrations several hundred times 400 
higher than the MBC values, concentration-dependent bactericidal activity is another 401 
important advantage of the agent, potentially resulting in rapid therapeutic response. This 402 
property along with the low potential of the agent to trigger resistance development suggests 403 
that its applicability will keep for a long time. As Ebrimycin
®
 gel can not be used on mucous 404 
membranes due to high alcohol content new formulations are also under development to be 405 
challenged in clinical trials to address broader indications. Being a registered active 406 
substance, primycin is a readily available tool in local therapy or prevention of infections 407 
caused by multiresistant Gram-positive bacteria, as well as in eradication of asymptomatic 408 
colorizations. 409 
 410 
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Legends to illustrations 503 
 504 
Fig. 1. The molecular structure of primycin. R1 substituent is O-arabinose, -H, or -OH group 505 
in components A, B, and C, respectively, and R2 is butyl, pentyl, or hexyl group in 506 
component subgroups 1, 2, and 3, respectively. Main components by mass ratio are A1 (~50 507 
% w/w), C1 (~15 % w/w), A3 (~7.5 % w/w), A2 (~6 % w/w), B1 (~6 % w/w). All the other 508 
components are below 5 % w/w. Molecular weights of the components are in the 930 – 1106 509 
g/mol range. 510 
 511 
 512 
Fig. 2. Pharmacodynamics of primycin in comparison with that of vancomycin. Time-kill 513 
curves of primycin (A, C, E), and vancomycin (B, D, F) against S. aureus ATCC 29213 (A, 514 
B), E. faecalis ATCC 29212 (C, D), and S. pneumoniae ATCC 49619 (E, F). Symbols: , 515 
growth control; , 1 × MIC; , 2 × MIC; , 4 × MIC; , 8 × MIC; dotted line, limit of 516 
detection (1.7 Log10 CFU/ml). 517 
 518 
 519 
